Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokoi, S.
Right arrow Articles by Inazawa, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokoi, S.
Right arrow Articles by Inazawa, J.
Clinical Cancer Research Vol. 9, 4705-4713, October 15, 2003
© 2003 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

TERC Identified as a Probable Target within the 3q26 Amplicon That Is Detected Frequently in Non-Small Cell Lung Cancers

Sana Yokoi, Kohichiroh Yasui, Toshihiko Iizasa, Issei Imoto, Takehiko Fujisawa and Johji Inazawa1

Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8519, Japan [S. Y., K. Y., I. I., J. I.]; Department of Thoracic Surgery, Chiba University Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan [S. Y., T. I., T. F.]; and CREST, Japan Science and Technology Corporation, Kawaguchi-city, Saitama 332-0012 Japan [K. Y., I. I., J. I.]

ABSTRACT

Purpose: Cell lines derived from non-small cell lung cancers (NSCLCs) revealed frequent high-level gains of chromosomal DNA at 3q23-q29 when examined by comparative genomic hybridization (CGH). Within this amplicon, a minimal common region of amplification in lung tumors had been mapped to 3q26 by earlier studies. The aim of the present work was to identify specific targets of the 3q26 amplification in NSCLCs.

Experimental Design: We examined genomic alterations in 19 NSCLC cell lines (10 derived from squamous cell carcinomas and 9 from adenocarcinomas) by using CGH and fluorescence in situ hybridization. We determined amplification and expression levels of four candidates (EVI1, TERC, SNO, and PIK3CA) in those cell lines and also in 25 primary NSCLC tumors. Because the TERC gene encodes the RNA component of human telomerase, we examined telomerase activity by the telomeric repeat amplification protocol (TRAP) assay.

Results: Copy numbers of EVI1 and TERC increased more than those of SNO and PIK3CA in our panel of NSCLC cell lines. Significant correlation between amplification and expression levels was observed only for TERC (P = 0.006), however, among these four candidate genes. Expression of TERC was also up-regulated in 24 (96%) of 25 primary NSCLC tumors compared with their nontumorous counterparts (P = 0.0001), and elevated expression of TERC was associated with high levels of telomerase activity (P = 0.048).

Conclusions: TERC is a likely target of the 3q26 amplification, and, therefore, may be a useful biomarker for diagnosis and an attractive, novel target for molecular therapy of NSCLC.

INTRODUCTION

Carcinoma of the lung is the leading cause of cancer mortality among both men and women throughout the world. NSCLC,2 which accounts for 75% to 80% of all lung cancers, consists of two major subtypes, squamous cell carcinoma and adenocarcinoma. Improvement in the efficacy of therapy for patients with NSCLC is a major public-health goal, and identification of specific genetic alterations in a given tumor could suggest optimal molecular targets for clinical management of these tumors.

Accumulated evidence suggests that multiple genetic alterations occurring sequentially in a cell lineage, at nucleotide as well as at chromosome levels, underlie the carcinogenic process in solid tumors, including NSCLCs (1) . Amplification of chromosomal DNA is one of the mechanisms capable of activating genes that contribute to the development and progression of cancer when they are overexpressed. We have detected novel regions of amplification in various types of cancer by CGH analyses and, from such amplicons, have identified a number of candidate oncogenes that were up-regulated by DNA amplification (2, 3, 4, 5, 6, 7) . Recently, we identified SKP2 as a target of 5p13 amplification in small-cell lung cancers (8) .

In the work reported here, we examined 19 NSCLC cell lines by CGH to explore genomic alterations that might affect the initiation and progression of this type of tumor. Among losses and gains involving several chromosomal regions, we found the most frequent HLGs, indicative of gene amplification, at 3q23-q29. Within the 3q23-q29 amplicon, a minimal common region of amplification had been mapped to 3q26 in previous studies of NSCLC (9, 10, 11, 12, 13) , in which an amplicon at 3q26 was detected in 25% of NSCLCs examined (14) . Gains in DNA copy number within 3q have been reported in 16.4% of solid tumors arising in 27 different types of tissue (15) , and in 40.2% of all types of lung cancer (15) . Other investigators have shown that a gain of 3q can serve as a marker for the transition from severe dysplasia to invasive carcinoma of the uterine cervix (16) , and that amplification at 3q26.3 is a parameter for tumor progression and poor prognosis in patients with head-and-neck squamous cell carcinomas (17) . Taken together, these lines of evidence strongly suggested that the 3q26 region harbors one or more target genes the amplification of which renders them oncogenic in tumors of various types.

Earlier studies in our laboratory indicated that SNO, a regulator of tumor growth factor ß (TGF-ß) signaling, was a probable target for amplification at 3q26 in esophageal squamous cell carcinomas (18) . Others have proposed PIK3CA, which encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), as the target for the 3q26 amplicon in ovarian cancers (19) and NSCLCs (20) . The 3q26 region contains other candidates, however, including EVI1 and TERC (21) . Overexpression of EVI1, resulting from rearrangement of DNA at 3q26, is associated with myeloid leukemia and myelodysplastic syndrome (22 , 23) . TERC encodes the RNA component of human telomerase, which acts as a template for the addition of telomeric repeat sequences (24) . To identify target(s) for the 3q26 amplification in NSCLC, we investigated amplification and expression levels of four candidate genes (EVI1, TERC, SNO, and PIK3CA), and TERC emerged as a probable target.

MATERIALS AND METHODS

Cell Lines and Primary Samples.
The 19 NSCLC cell lines chosen for this study (9 from adenocarcinomas and 10 from squamous cell carcinomas) were established and described previously (Table 1)Citation . ABC-1, VMRC-LCD, and Lc-1sq were maintained in DMEM supplemented with 10% FCS and penicillin-streptomycin (P-S). ACC-LC-73 was maintained in RPMI 1640 supplemented with 5% FCS and P-S. All of the others were maintained in RPMI 1640 supplemented with 10% FCS and P-S.


View this table:
[in this window]
[in a new window]
  		Table 1 Summary of 19 NSCLC cell lines

 
We obtained primary samples from 25 patients with NSCLC (13 adenocarcinomas and 12 squamous-cell carcinomas) at the Chiba University Hospital, Chiba, Japan. Adjacent nontumorous lung tissues from each patient were used as controls. Before initiation of the present study, informed consent was obtained in the formal style approved by ethics committees.

CGH.
CGH was performed using directly fluorochrome-conjugated DNA as described by Kallioniemi et al. (25) , with minor modification (26) . Briefly, genomic DNA from each NSCLC cell line was labeled with Spectrum Green-dUTP (Vysis, Chicago, lL), and reference DNA from normal peripheral blood lymphocytes was labeled with Spectrum Orange-dUTP (Vysis) by nick translation. Labeled tumor and normal DNAs (250 ng each), together with 10 µg of Cot-1 DNA (Life Technologies, Inc., Gaithersburg, MD), were hybridized to normal male metaphase chromosome spreads. The slides were washed and counterstained with 4',6'-diamidino-2-phenylindole (DAPI). Shifts in CGH profiles were rated as gains and losses if they reached at least the 1.2 and 0.8 thresholds respectively. Overrepresentations were considered to be HLGs when the fluorescence ratio exceeded 1.5, as described elsewhere (2) .

FISH.
We performed FISH experiments, using as probes, four BACs described previously (8 , 27) . We selected these BACs (RP11–33A1, RP11–816J6, RP11–543D10, and GS-162H01), containing respectively the EVI1, TERC, SNO, and PIK3CA genes, on the basis of their locations according to databases provided by the University of California-Santa Cruz3 and the NCBI.4 Briefly, each probe was labeled by nick-translation with biotin-16-dUTP or digoxigenin-11-dUTP (Roche Diagnostics, Tokyo, Japan) and was hybridized to metaphase chromosomes. Hybridization signals for multicolor FISH were detected as described elsewhere (27) .

Southern- and Northern-Blot Analyses.
cDNA sequences of TERC (I.M.A.G.E. clone ID, 2727679), and PIK3CA (I.M.A.G.E. clone ID, 250142) were purchased from Incyte Genomics (Palo Alto, CA) and were used as probes for Southern and Northern blots. A cDNA clone of EVI1 was kindly provided by Dr. H. Hirai, University of Tokyo, Tokyo, Japan (28) . For SNO, we designed specific PCR primers [forward (F), 5'-GGTGACCATGTTTCTCAGAC-3' and reverse (R), 5'-CTGACTAAGTTGCAAGTGGC-3'] on the basis of its cDNA sequence (29) and used the PCR product as a probe. Southern and Northern hybridization experiments were performed as described elsewhere (5) .

Real-Time Quantitative RT-PCR.
We quantified mRNA levels of EVI1, TERC, SNO, and PIK3CA using a real-time fluorescence detection method described previously (7) . Briefly, total RNA was isolated from primary NSCLC tumors and nontumorous lung tissues adjacent to each of the tumors, using Trizol (Invitrogen, Carlsbad, CA). To eliminate residual genomic DNA, the RNA extracts were treated with RNase-free DNaseI (Takara, Tokyo, Japan) before RT-PCR. Single-stranded cDNAs were generated using Superscript II reverse transcriptase (Invitrogen) following the manufacturer’s directions. Real-time quantitative PCR experiments were performed with an ABI Prism 7900 sequence-detection system (Applied Biosystems, Foster City, CA), using SYBR Green PCR Master Mix according to the manufacturer’s protocol. The primer sequences were as follows: for EVI1, (forward, 5'-TTCTGAAGCTGAGCTGTCTTCTTTT-3', and reverse, 5'-ATCTGTACCTGCGATTTGGACTTT-3'); for TERC, (F, 5'-GTGGTGGCCATTTTTTGTCTAAC-3', and R, 5'-TGCTCTAGAATGAACGGTGGAA-3'); for SNO, (F, 5'-TCAGCCTGATGCTCCGTGTA-3', and R, 5'-AAGCCCCAGTGGCAAGTTC-3'); and for PIK3CA, (F, 5'-CAGGGCTTGCTGTCTCCTCTAA-3', and R, 5'-TTTGCAGAAGACATAATTCGACACT-3'). Each primer was designed using Primer Express software (Applied Biosystems) on the basis of sequence data obtained from the NCBI database. GAPDH (Applied Biosystems) served as a reference; i.e., each sample was normalized on the basis of its GAPDH content. The thermal cycling conditions were as follows: 10 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Duplicate PCR amplifications were performed for each sample.

Telomerase Assay.
Telomerase activity was assayed by TRAPeze Telomerase Detection kits (Intergen, Purchase, NY) according to the manufacturer’s protocol. The methodology is based on a modification of the original method described by Kim et al. (30) . Briefly, 1.0 x 106 NSCLC cells in logarithmic growth phase were lysed in 200 µl of CHAPS buffer (Intergen). After maintenance at 4°C for 30 min, the lysate was centrifuged at 12,000 x g for 20 min at 4°C. The supernatant (100 ng of protein) was subjected to the TRAP assay. After the TRAPeze reaction mixture was added, the solution was incubated at 30°C for 30 min to allow telomerase-mediated extension of a substrate oligonucleotide. The extended products were then amplified by 30 cycles of PCR (94°C for 30 s, 59°C for 30 s, and 72°C for 1 min). The PCR products were electrophoresed on 15% nondenaturing polyacrylamide gels, which were then stained with SYBR Green I (Molecular Probes, Eugene, OR). Positive enzyme activity was confirmed when a ladder of products with six-base increments starting at 50 nucleotides and a band representing the 36-bp ITAS (Intergen), were observed. The telomerase quantification control template (TSR8) from the TRAP-ese Kit was used as a positive control for estimating the telomeric repeats extended by telomerase. As a negative control, CHAPS buffer (no cellular extract) was used. The intensities of the TRAP products and ITAS bands were measured by a Bio-Imaging Analyzer (LAS 1000; Fujifilm, Tokyo, Japan) and MacBAS software (Fujifilm). The quantification of telomerase activity was calculated according to the manufacturer’s protocol as the total product generated (TPG) by formula: [Total of TRAP product ladder bands from each sample/ITAS band in each assay]/[Total of TRAP product ladder bands from TSR8/ITAS band in TSR8] x 100 = TPG (units).

Statistical Analysis.
All of the statistical analyses were performed with Stat-View 4.5 statistical software. Relationships between relative copy numbers and expression levels of each gene were determined using the Spearman’s test, with determination of correlation coefficients (r) and associated probabilities (P). The Wilcoxon signed-rank test was used to compare paired tumor and nontumor tissues for mRNA levels of each gene. The relationship between telomerase activity and mRNA levels of TERC was assessed by the Mann-Whitney test. Ps of <0.05 were considered significant.

RESULTS

Genomic Imbalances in NSCLC Cell Lines.
An overview of the genetic changes we detected among 19 NSCLC cell lines is shown in Fig. 1Citation . All of the lines (100%) showed copy-number aberrations, and gains predominated over losses in a ratio of 1.5:1. The average number of aberrations per cell line was 16.8 (range, 7–28); average numbers of gains and losses were 10.0 (range, 6–14) and 6.8 (range, 1–14), respectively.



View larger version (43K):
[in this window]
[in a new window]
  		Fig. 1. Summary of genetic imbalances detected by CGH in 19 NSCLC cell lines. The 22 autosomes and X chromosome are represented by ideograms showing G-banding patterns. The computerized green-to-red profiles: vertical lines on the left (red) of each chromosome ideogram, losses of genomic material; vertical lines on the right (green), copy-number gains. Yellow rectangles, HLGs. The number at the top of each vertical line, the cell line (see Table 1Citation ).

 
Common Regions Involved in DNA Copy-Number Aberrations.
Table 2Citation indicates that the minimal common regions of loss that occurred most frequently were at 13q21.1-q32 (12 cell lines, 63%); 8p22-p23.3, 9p21-p24, 9p11-p21, and 18q12.3-q23 (nine each, 47%); and 8p11.1-p21 (eight lines, 42%). The minimal regions involving copy-number gains were identified at Xq22.1-q28 (15 cell lines, 79%); 5p14-p15.3 (14, 74%); Xq11.1-q21.3 (13, 68%); 3q23-q29 (12, 63%); 5p11-p13.3 and 8q22.1-q23 (11 each, 58%); 7p15.1-p22, 7p11.1-p14, and 8q24.1-q24.3 (10 each, 53%); 1q31-q41 and 1q42.1-q44 (nine each, 47%); and 6p21.3-p25 and 7q22.1-q32 (eight each, 42%). The smallest regions of HLGs were seen at 3q23-q29 and 5p14-p15.3 (five cases each); 5p11-p13.3 (four cases); 7q21.1-q31.3 and 8q23-q24.3 (three cases each); and 2p22-p25.2 and Xq13-q21.2 (two cases each).


View this table:
[in this window]
[in a new window]
  		Table 2 Minimal overlapping regions of common DNA copy-number changes in NSCLC cell lines

 
Amplification of EVI1, TERC, SNO, and PIK3CA in NSCLC Cell Lines.
We focused further examination on the common region within the 3q23-q29 amplicon that was most frequently involved in HLGs. As candidate targets for the amplicon, we selected four genes (EVI1, TERC, SNO, and PIK3CA) located at 3q26. To generate the amplicon map, we performed FISH with four BACs, each containing one of these four genes, as probes on the five NSCLC cell lines that exhibited HLGs in the 3q26 region. The precise locus of each BAC had been confirmed before the study, by FISH on normal prometaphase chromosomes (data not shown). In Lc-1sq cells we counted 16 FISH signals for EVI1 and TERC, 13 for SNO, and 10 for PIK3CA (Fig. 2, A, B, and D)Citation . The other four cell lines (PC-10, VMRC-LCP, HUT-29, and ABC-1) showed eight, seven, six, and five FISH signals for each of the four genes, respectively (Fig. 2, A, C, and E)Citation . These findings suggested that EVI1 and TERC lay within a more critical region of the 3q26 amplicon in NSCLC cells than did SNO and PIK3CA.



View larger version (39K):
[in this window]
[in a new window]
  		Fig. 2. Map of the amplicon at 3q26 and representative images of two-color FISH in NSCLC cell lines. A, to the right of the chromosome 3 ideogram, the positions of four genes (EVI1, TERC, SNO, and PIK3CA) according to the University of California-Santa Cruz3 and NCBI4 databases, and the copy number per cell determined by FISH in five NSCLC cell lines. Sq, squamous cell carcinoma. Ad, adenocarcinoma. B–E, representative images of two-color FISH on metaphase chromosomes from Lc-1sq cells (B, D) and ABC-1 cells (C, E). Lc-1sq cells showed 16 FISH signals for EVI1 (B, green), 13 signals for SNO (B, red), 16 signals for TERC (D, green), and 10 signals for PIK3CA (D, red). ABC-1 cells generated five FISH signals each for EVI1 (C, green), SNO (C, red), TERC (E, green), and PIK3CA (E, red).

 
Relationship between Amplification and Expression Levels of Four Genes in NSCLC Cell Lines.
We examined amplification and expression levels for EVI1, TERC, SNO, and PIK3CA in our panel of 19 NSCLC cell lines by Southern and Northern blotting. All four genes exhibited amplification in multiple cell lines compared with normal genomic DNA: EVI1 in 7 (37%) of the 19 lines; TERC in 9 (47%); SNO in 7 (37%); and PIK3CA in 5 (26%; Fig. 3ACitation ). EVI1 was overexpressed in 2 (11%) of the 19 lines, TERC in 5 (26%), SNO in 5 (26%), and PIK3CA in 2 (11%; Fig. 3BCitation ). However, the expression patterns of the four genes in question did not always accord with their amplification patterns (Fig. 3)Citation . For example, in Lc-1sq cells, TERC was overexpressed but EVI1 was not (Fig. 3B)Citation , although both genes were amplified (Figs. 2ACitation and 3ACitation ). Significant correlation between amplification and expression was observed only for TERC (Spearman’s rank correlation test, r = 0.647; P = 0.006; Fig. 4Citation ).



View larger version (61K):
[in this window]
[in a new window]
  		Fig. 3. Amplification and overexpression of four genes (EVI1, TERC, SNO, and PIK3CA) lying within the 3q26 amplicon in 19 NSCLC cell lines, 9 derived from adenocarcinomas (left panels) and 10 from squamous cell carcinomas (right panels). *, cell lines that showed amplification and/or overexpression of these genes. A, Southern blots containing 5 µg of genomic DNA derived from NSCLC cell lines or normal peripheral lymphocytes. Additional EcoRI fragments of PIK3CA were present in some cell lines because of polymorphisms. B, Northern blot analyses using 10 µg of total RNA from each of the same NSCLC cell lines; GAPDH served as a quantity-control probe.

 


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 4. Correlation between amplification level (copy number) and expression level for EVI1 (A), TERC (B), SNO (C), and PIK3CA (D). From the intensity of each signal on a Southern blot, a relative copy number (X axis) was obtained that was then normalized by dividing it by the value of the normal control band after subtracting background. From the intensity of each signal on a Northern blot, a normalized expression level (Y axis) was calculated that was normalized by dividing it by the corresponding reference value obtained from GAPDH.

 
Expression of EVI1, TERC, SNO, and PIK3CA in Primary NSCLC Tumors.
When we determined expression levels of EVI1, TERC, SNO, and PIK3CA in paired tumor and nontumor tissues from 25 NSCLC patients using real-time quantitative RT-PCR, EVI1 was significantly overexpressed in 19 (76%) of the tumors compared with their counterpart nontumorous tissues (Wilcoxon signed-rank test, P = 0.014; Fig. 5ACitation ). Expression of TERC was even more strongly up-regulated in 24 (96%) of the 25 tumors (P = 0.0001; Fig. 5BCitation ). No expression of TERC was detectable in 22 of the 25 nontumorous tissues, although this gene was expressed in 23 of 25 tumors. SNO and PIK3CA showed higher expression in 16 (64%) and 15 (60%) of tumors, respectively, than in nontumorous tissues without statistical significance (Fig. 5, C and D)Citation .



View larger version (33K):
[in this window]
[in a new window]
  		Fig. 5. Relative expression of EVI1 (A), TERC (B), SNO (C), and PIK3CA (D) in 25 primary NSCLC tumors and their nontumorous counterparts. The mRNA level of each gene was evaluated by real-time quantitative RT-PCR and was normalized by expression of GAPDH.

 
Telomerase Activity.
Next we investigated the effect of TERC overexpression on telomerase activity in NSCLC cells using the PCR-based TRAP assay (30) . Enzymatic activity was detected in 18 (95%) of the 19 NSCLC cell lines (Fig. 6)Citation . To examine the relationship between telomerase activity and expression levels of TERC mRNA, the cell lines were divided into high (n = 8) and low (n = 11) groups according to the mean mRNA levels of TERC that were determined by real-time quantitative RT-PCR. Elevated expression of TERC was significantly associated with high telomerase activity (Mann-Whitney test, P = 0.048; Fig. 6BCitation ).



View larger version (22K):
[in this window]
[in a new window]
  		Fig. 6. Association between telomerase activity and levels of TERC mRNA in NSCLC cells. A, representative images from the TRAP assay of five NSCLC cell lines, two (LK-2 and Lc-1sq) that had shown overexpression of TERC and three (HUT-15, RERF-LC-OK, and SK-LC-3) in which the gene was not overexpressed. The 36-bp ITAS is noted. B, telomerase activity in NSCLC cell lines with high versus low levels of TERC mRNA. Nineteen NSCLC cell lines were divided into high (n = 8) and low (n = 11) groups at the mean of the mRNA levels of TERC. Telomerase activity was determined as described in "Materials and Methods." Horizontal bars, means ± SD.

 
DISCUSSION

Our CGH studies revealed that amplification of the 3q26 region occurred frequently in cell lines derived from NSCLCs. Results of subsequent experiments suggested that TERC was the most probable target for this amplicon among the four candidate genes examined: (a) DNA copy numbers of EVI1 and TERC increased more than those of SNO and PIK3CA in the Lc-1sq cell line (Fig. 2A)Citation ; (b) significant correlation between amplification and expression levels was observed only for TERC (Fig. 4)Citation ; (c) TERC was the gene most frequently up-regulated in primary NSCLC tumors compared with their nontumorous counterparts (Fig. 5)Citation ; and (d) elevated expression of TERC was significantly associated with high levels of telomerase activity (Fig. 6)Citation .

Telomerase helps to stabilize the length of telomeres in human stem cells, reproductive cells, and cancer cells by adding TTAGGG repeats onto the telomeres, using its intrinsic RNA (TERC) as a template for reverse transcription (31) . Telomerase activity has been observed in almost all human tumors, but not in normal tissues (30) . The data shown in Fig. 5BCitation clearly demonstrated that no detectable TERC was expressed in most of the nontumorous lung tissues adjacent to the NSCLCs we examined, but its expression was common in primary tumors, suggesting that TERC could be a useful biomarker for the diagnosis of NSCLC. Expression of an antisense TERC in human cell lines represses telomerase activity, shortens telomeres, and eventually leads to cell crisis (24) . Together, these observations support the idea that TERC would be an attractive, novel target for molecular-based therapy for NSCLC.

Although we found a significant link between the expression level of TERC and enzymatic activity of telomerase (Fig. 6)Citation , others have noted that TERC expression can be detected in the absence of telomerase activity and that up-regulation of TERC is an early event in carcinogenesis, whereas telomerase activity is detected only in later stages (32, 33, 34) . Telomerase activity is regulated by multiple factors. It is known that expression levels of TERT mRNA are correlated with telomerase activity in human cancer (35) . Therefore, we determined expression levels of TERT as well as TERC in primary NSCLC tumors. There was no significant association between expression levels of TERT and TERC (data not shown); suggesting that up-regulation of TERC might contribute to the activation of telomerase independent of TERT. Our panel of NSCLC cell lines frequently showed losses of DNA in the region harboring PINX1 (8p23; Table 2Citation ; Fig. 1Citation ); PINX1 encodes a PIN2/TRF1 binding protein that inhibits telomerase activity (36) . These genomic changes, together with amplification of TERC at 3q26, might collaborate to activate telomerase in NSCLCs.

Earlier studies of NSCLC indicated that gains in DNA copy number at 3q26 occurred more frequently in squamous cell carcinomas than in adenocarcinomas (11 , 12 , 20 , 37) . Soder et al. (32) reported that expression of TERC in NSCLC, as determined by in situ hybridization, was almost confined to squamous cell carcinoma and rare in adenocarcinoma. In our CGH studies, however, gain at 3q26 was found in 6 of the 10 cell lines derived from squamous cell carcinoma and in 6 of the 9 adenocarcinoma lines (Table 1Citation ; Fig. 1Citation ). TERC was frequently overexpressed as well as amplified in our cell lines derived from either type of tumor (Fig. 3)Citation ; moreover, we observed up-regulation of TERC expression in all of the 12 primary squamous cell carcinoma tumors that we examined, and in 12 of the 13 primary adenocarcinomas (Fig. 5)Citation . Our results suggested that TERC was a common target of 3q26 amplification in these NSCLCs.

Because the 3q26 amplicon in NSCLCs is estimated to be more than 30 Mb long (20) , TERC is unlikely to be the only target gene. Other candidates include BCHE (38) , SLC2A2 (38) , EIF5A2 (39) , and SST (20) , as well as unidentified transcripts. Activated EVI1, SNO, and/or PIK3CA may also collaborate for progression of NSCLC.

Functional studies are needed to clarify the effect of TERC on the initiation and progression of NSCLC, because TERC may become a valuable diagnostic biomarker and a novel therapeutic target for this type of lung cancer.

FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Supported by: Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to J. I.), and Grants-in-Aid for Scientific Research from the Japan Society for the Program of Science (J. I., K. Y.) and from CREST of the Japan Science and Technology Corporation (J. I., K. Y.).

1 To whom requests for reprints should be addressed, at Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. Phone: 81-3-5803-5820; Fax: 81-3-5803-0244; E-mail: johinaz.cgen{at}mri.tmd.ac.jp Back

2 The abbreviations used are: NSCLC, non-small cell lung cancer; TRAP, telomeric repeat amplification protocol; CGH, comparative genomic hybridization; HLG, high-level gain; FISH, fluorescence in situ hybridization; BAC bacterial artificial chromosome; NCBI, National Center for Biotechnology Information; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; ITAS, internal telomerase assay standard. Back

3 Internet address: http://genome.ucsc.edu/. Back

4 Internet address: http://www.ncbi.nlm.nih.gov/. Back

Received 2/24/03; revised 6/11/03; accepted 6/17/03.

REFERENCES

  1. Takahashi T. Lung cancer: an ever increasing store of in-depth basic knowledge and the beginning of its clinical application. Oncogene, 21: 6868-6869, 2002.[CrossRef][Medline]
  2. Shinomiya T., Mori T., Ariyama Y., Sakabe T., Fukuda Y., Murakami Y., Nakamura Y., lnazawa J. Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DP1 gene in the 13q34 amplicon. Genes Chromosomes Cancer, 24: 337-344, 1999.[CrossRef][Medline]
  3. Fukuda Y., Kurihara N., Imoto I., Yasui K., Yoshida M., Yanagihara K., Park J. G., Nakamura Y., Inazawa J. CD44 is a potential target of amplification within the 11p13 amplicon detected in gastric cancer cell lines. Genes Chromosomes Cancer, 29: 315-324, 2000.[CrossRef][Medline]
  4. Yang Z. Q., Imoto I., Fukuda Y., Pimkhaokham A., Shimada Y., Imamura M., Sugano S., Nakamura Y., Inazawa J. Identification of a novel gene, GASC1, within an amplicon at 9p23–24 frequently detected in esophageal cancer cell lines. Cancer Res., 60: 4735-4739, 2000.[Abstract/Free Full Text]
  5. Yasui K., Imoto I., Fukuda Y., Pimkhaokham A., Yang Z. Q., Naruto T., Shimada Y., Nakamura Y., Inazawa J. Identification of target genes within an amplicon at 14q12–q13 in esophageal squamous cell carcinoma. Genes Chromosomes Cancer, 32: 112-118, 2001.[CrossRef][Medline]
  6. Imoto I., Yang Z. Q., Pimkhaokham A., Tsuda H., Shimada Y., Imamura M., Ohki M., Inazawa J. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res., 61: 6629-6634, 2001.[Abstract/Free Full Text]
  7. Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology, 35: 1476-1484, 2002.[CrossRef][Medline]
  8. Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T., Fujisawa T., Terasaki T., Horii A., Takahashi T., Hirohashi S., Inazawa J. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am. J. Pathol., 161: 207-216, 2002.[Abstract/Free Full Text]
  9. Brass N., Ukena I., Remberger K., Mack U., Sybrecht G. W., Meese E. U. DNA amplification on chromosome 3q26.1-q26.3 in squamous cell carcinoma of the lung detected by reverse chromosome painting. Eur. J. Cancer, 32: 1205-1208, 1996.[CrossRef]
  10. Balsara B. R., Sonoda G., du Manoir S., Siegfried J. M., Gabrielson E., Testa J. R. Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res., 57: 2116-2120, 1997.[Abstract/Free Full Text]
  11. Petersen I., Bujard M., Petersen S., Wolf G., Goeze A., Schwendel A., Langreck H., Gellert K., Reichel M., Just K., du Manoir S., Cremer T., Dietel M., Ried T. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res., 57: 2331-2335, 1997.[Abstract/Free Full Text]
  12. Bjorkqvist A. M., Husgafvel-Pursiainen K., Anttilam S., Karjalainen A., Tammilehto L., Mattson K., Vainio H., Knuutila S. DNA gains in 3q occur frequently in squamous cell carcinoma of the lung, but not in adenocarcinoma. Genes Chromosomes Cancer, 22: 79-82, 1998.[CrossRef][Medline]
  13. Balsara B. R., Testa J. R. Chromosomal imbalances in human lung cancer. Oncogene, 21: 6877-6683, 2002.[CrossRef][Medline]
  14. Knuutila S., Björkvist A. M., Autio K., Tarkkanen M., Wolf M., Monni O., Szymanska J., Larramendy M. L., Tapper J., Pere H., EI-Rifai W., Hemmer S., Wasenius V. M., Vidgren V., Zhu Y. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am. J. Pathol., 152: 1107-1123, 1998.[Abstract]
  15. Rooney P. H., Murray G. I., Stevenson D. A., Haites N. E., Cassidy J., McLeod H. L. Comparative genomic hybridization and chromosomal instability in solid tumours. Br. J. Cancer, 80: 862-873, 1999.[CrossRef][Medline]
  16. Heselmeyer K., Schrock E., du Manoir S., Blegen H., Shah K., Steinbeck R., Auer G., Ried T. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc. Natl. Acad. Sci. USA, 93: 479-484, 1996.[Abstract/Free Full Text]
  17. Singh B., Stoffel A., Gogineni S., Poluri A., Pfister D. G., Shaha A. R., Pathak A., Bosl G., Cordon-Cardo C., Shah J. P., Rao P. H. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas. Am. J. Pathol., 161: 365-371, 2002.[Abstract/Free Full Text]
  18. Imoto I., Pimkhaokham A., Fukuda Y., Yang Z. Q., Shimada Y., Nomura N., Hirai H., Imamura M., Inazawa J. SNO is a probable target for gene amplification at 3q26 in squamous-cell carcinomas of the esophagus. Biochem. Biophys. Res. Commun., 286: 559-565, 2001.[CrossRef][Medline]
  19. Shayesteh L., Lu Y., Kuo W. L., Baldocchi R., Godfrey T., Collins C., Pinkel D., Powell B., Mills G. B., Gray J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 21: 99-102, 1999.[CrossRef][Medline]
  20. Massion P. P., Kuo W. L., Stokoe D., Olshen A. B., Treseler P. A., Chin K., Chen C., Polikoff D., Jain A. N., Pinkel D., Albertson D. G., Jablons D. M., Gray J. W. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res., 62: 3636-3640, 2002.[Abstract/Free Full Text]
  21. Soder A. I., Hoare S. F., Muir S., Going J. J., Parkinson E. K., Keith W. N. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene, 14: 1013-1021, 1997.[CrossRef][Medline]
  22. Morishita K., Parganas E., William C. L., Whittaker M. H., Drabkin H., Oval J., Taetle R., Valentine M. B., Ihle J. N. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proc. Natl. Acad. Sci. USA, 89: 3937-3941, 1992.[Abstract/Free Full Text]
  23. Ogawa S., Kurokawa M., Tanaka T., Mitani K., Inazawa J., Hangaishi A., Tanaka K., Matsuo Y., Minowada J., Tsubota T., Yazaki Y., Hirai H. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene, 13: 183-191, 1996.[Medline]
  24. Feng J., Funk W. D., Wang S. S., Weinrich S. L., Avilion A. A., Chiu C. P., Adams R. R., Chang E., Allsopp R. C., Yu J., Le S., West M. D., Harley C. B., Andrews W. H., Greider C. W., Villeponteau B. The RNA component of human telomerase. Science (Wash. DC), 269: 1236-1241, 1995.[Abstract/Free Full Text]
  25. Kallioniemi A., Kallioniemi O. P., Sudar D., Rutovitz D., Gray J. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science (Wash. DC), 258: 818-821, 1992.[Abstract/Free Full Text]
  26. Ariyama Y., Mori T., Shinomiya T., Sakabe T., Fukuda Y., Kanamaru A., Yamada Y., Isobe M., Seto M., Nakamura Y., Inazawa J. Chromosomal imbalances in adult T-cell leukemia revealed by comparative genomic hybridization: gains at 14q32 and 2p16–22 in cell lines. J. Hum. Genet., 44: 357-363, 1999.[CrossRef][Medline]
  27. Inazawa J., Saito H., Ariyama T., Abe T., Nakamura Y. High-resolution cytogenetic mapping of 342 new cosmid markers including 43 RFLP markers on human chromosome 17 by fluorescence in situ hybridization. Genomics, 17: 153-162, 1993.[CrossRef][Medline]
  28. Kurokawa M., Mitani K., Irie K., Matsuyama T., Takahashi T., Chiba S., Yazaki Y., Matsumoto K., Hirai H. The oncoprotein Evi-1 represses TGF-ß signalling by inhibiting Smad3. Nature (Lond.), 394: 92-96, 1998.[CrossRef][Medline]
  29. Nomura N., Sasamoto S., Ishii S., Date T., Matsui M., Ishizaki R. Isolation of human cDNA clones of ski and the ski-related gene, sno. Nucleic Acids Res., 17: 5489-5500, 1989.[Abstract/Free Full Text]
  30. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Wash. DC), 266: 2011-2015, 1994.[Abstract/Free Full Text]
  31. Shay J. W., Zou Y., Hiyama E., Wright W. E. Telomerase and cancer. Hum. Mol. Genet., 10: 677-685, 2001.[Abstract/Free Full Text]
  32. Soder A. I., Going J. J., Kaye S. B., Keith W. N. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene, 16: 979-983, 1998.[CrossRef][Medline]
  33. Avilion A. A., Piatyszek M. A., Gupta J., Shay J. W., Bacchetti S., Greider C. W. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res., 56: 645-650, 1996.[Abstract/Free Full Text]
  34. Blasco M. A., Rizen M., Greider C. W., Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat. Genet., 12: 200-204, 1996.[CrossRef][Medline]
  35. Liu J. P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J., 13: 2091-2104, 1999.[Abstract/Free Full Text]
  36. Zhou X. Z., Lu K. P. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell, 107: 347-359, 2001.[CrossRef][Medline]
  37. Pei J., Balsara B. R., Li W., Litwin S., Gabrielson E., Feder M., Jen J., Testa J. R. Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes Chromosomes Cancer, 31: 282-287, 2001.[CrossRef][Medline]
  38. Brass N., Racz A., Heckel D., Remberger K., Sybrecht G. W., Meese E. U. Amplification of the genes BCHE and SLC2A2 in 40% of squamous cell carcinoma of the lung. Cancer Res., 57: 2290-2294, 1997.[Abstract/Free Full Text]
  39. Guan X. Y., Sham J. S., Tang T. C., Fang Y., Huo K. K., Yang J. M. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res., 61: 3806-3809, 2001.[Abstract/Free Full Text]
  40. Kobayashi S., Okada S., Inaba H., Syoji W., Hasumi T., Sato N., Fujimura S. Culture and growth characteristics of human non-small cell lung cancer cells (in Japanese). Kosankinbyo Kenkyu-Zassi, 42: 73-83, 1990.
  41. Giard D. J., Aaronson S. A., Todaro G. J., Arnstein P., Kersey J. H., Dosik H., Parks W. P. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J. Natl. Cancer Inst. (Bethesda), 51: 1417-1423, 1973.
  42. Hiraki S., Miyai M., Seto T., Tamura T., Watanabe Y., Ozawa S., Ikeda H., Nakata Y., Ohnoshi T., Kimura I. Establishment of human continuous cell lines from squamous cell, adeno- and small cell carcinoma of the lung and the results of heterotransplantation. Japanese Journal of Lung Cancer, 22: 53-58, 1982.
  43. Kyoizumi S., Akiyama M., Kouno N., Kobuke K., Hakoda M., Jones S. L., Yamakido M. Monoclonal antibodies to human squamous cell carcinoma of the lung and their application to tumor diagnosis. Cancer Res., 45: 3274-3281, 1985.[Abstract/Free Full Text]
  44. Hirai K., Shimada H., Ogawa T., Taji S. The spread of human lung cancer cells on collagens and its inhibition by type III collagen. Clin. Exp. Metastasis, 9: 517-527, 1991.[CrossRef][Medline]
  45. Lee Y. C., Saijo N., Sasaki Y., Takahashi H., Sakurai M., Ishihara J., Hoshi A., Chen K. M., Hamburger A. W. Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay. Jpn. J. Clin. Oncol., 15: 637-644, 1985.[Abstract/Free Full Text]
  46. Yamakawa H., Baba M., Yamaguchi Y. In vivo invasion assay of low passage cultured cells derived from human lung cancer using deepithelialized rat tracheas xenotransplanted into nude mice. Cancer Res., 50: 7358-7363, 1990.[Abstract/Free Full Text]
  47. Anger B. R., Lloyd K. O., Oettgen H. F., Old L. J. Mouse monoclonal IgM antibody against human lung cancer line SK-LC-3 with specificity for H(O) blood group antigen. Hybridoma, 1: 139-147, 1982.[Medline]
  48. Appelhans B., Ender B., Sachse G., Nikiforov T., Appelhans H., Ebert W. Related articles. Secretion of antileucoprotease from a human lung tumor cell line. FEBS Lett., 224: 14-18, 1987.
  49. Yamashita J., Tashiro K., Yoneda S., Kawahara K., Shirakusa T. Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer. Chest, 109: 1328-1334, 1996.[Abstract/Free Full Text]
  50. Inoue S., Mizuno S., Ito M., Ohnuma T. Flow cytometric analyses of the characteristics of tumor cells treated with two platinum compounds: 1,1-cyclobutanedicarboxylato(2-aminomethylpyrrolidine)-platinum(II) and cisplatin. Jpn. J. Cancer Res., 83: 1231-1240, 1992.[Medline]
  51. Hida T., Ariyoshi Y., Kuwabara M., Sugiura T., Takahashi T., Takahashi T., Hosoda K., Niitsu Y., Ueda R. Glutathione S-transferase levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn. J. Clin. Oncol., 23: 14-19, 1993.[Abstract/Free Full Text]
  52. Fogh J., Wright W. C., Loveless J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. (Bethesda), 58: 209-214, 1977.



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
M. N. Chau, L. H. El Touny, S. Jagadeesh, and P. P. Banerjee
Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3
Carcinogenesis, November 1, 2007; 28(11): 2282 - 2290.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Nanjundan, Y. Nakayama, K. W. Cheng, J. Lahad, J. Liu, K. Lu, W.-L. Kuo, K. Smith-McCune, D. Fishman, J. W. Gray, et al.
Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer
Cancer Res., April 1, 2007; 67(7): 3074 - 3084.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Pelosi, B. Del Curto, M. Trubia, A. G. Nicholson, M. Manzotti, G. Veronesi, L. Spaggiari, P. Maisonneuve, F. Pasini, A. Terzi, et al.
3q26 Amplification and Polysomy of Chromosome 3 in Squamous Cell Lesions of the Lung: A Fluorescence In situ Hybridization Study
Clin. Cancer Res., April 1, 2007; 13(7): 1995 - 2004.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Sunde, H. Donninger, K. Wu, M. E. Johnson, R. G. Pestell, G. S. Rose, S. C. Mok, J. Brady, T. Bonome, and M. J. Birrer
Expression Profiling Identifies Altered Expression of Genes That Contribute to the Inhibition of Transforming Growth Factor-{beta} Signaling in Ovarian Cancer.
Cancer Res., September 1, 2006; 66(17): 8404 - 8412.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J.C. Slebos, Y. Yi, K. Ely, J. Carter, A. Evjen, X. Zhang, Y. Shyr, B. M. Murphy, A. J. Cmelak, B. B. Burkey, et al.
Gene Expression Differences Associated with Human Papillomavirus Status in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., February 1, 2006; 12(3): 701 - 709.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. P. Regala, C. Weems, L. Jamieson, A. Khoor, E. S. Edell, C. M. Lohse, and A. P. Fields
Atypical Protein Kinase C{iota} Is an Oncogene in Human Non-Small Cell Lung Cancer
Cancer Res., October 1, 2005; 65(19): 8905 - 8911.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
H. Izumi, J. Inoue, S. Yokoi, H. Hosoda, T. Shibata, M. Sunamori, S. Hirohashi, J. Inazawa, and I. Imoto
Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers
Hum. Mol. Genet., April 15, 2005; 14(8): 997 - 1007.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Buonamici, D. Li, F. M. Mikhail, A. Sassano, L. C. Platanias, O. Colamonici, J. Anastasi, and G. Nucifora
EVI1 Abrogates Interferon-{alpha} Response by Selectively Blocking PML Induction
J. Biol. Chem., January 7, 2005; 280(1): 428 - 436.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yokoi, S.
Right arrow Articles by Inazawa, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokoi, S.
Right arrow Articles by Inazawa, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online